Navigation Links
New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
Date:5/9/2008

- Fifth International Phase III Study Shows Positive Results with X-ray

Data -

NUTLEY, N.J., May 9 /PRNewswire/ -- Roche today announced one-year results from a new two-year Phase III study showing that ACTEMRA(TM) (tocilizumab) can significantly inhibit progression of structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. The study also demonstrated that ACTEMRA reduces disease signs and symptoms at one year. The LITHE study is the fifth international Phase III ACTEMRA trial to successfully meet its primary endpoints in patients with moderate to severe RA.

The one-year data from LITHE (TociLIzumab Safety and THE Prevention of Structural Joint Damage) trial showed that a greater proportion of patients treated with ACTEMRA (4 mg/kg or 8 mg/kg) plus methotrexate versus placebo plus methotrexate over 52 weeks achieved a significant reduction in the progression of structural joint damage, which is critical to RA patients because joint damage leads to disability. The study analysis included 1,196 patients from 137 trial sites in 15 countries. Twenty-eight percent of the patients were from the United States.

ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arm of the LITHE trial were upper respiratory tract infections, nasopharyngitis, hypertension, headache and an increase in transaminases.

"At one year, the results from the LITHE trial clearly demonstrate that ACTEMRA could be an effective component in the battle against the long-term debilitating effects of RA, including joint damage and loss of physical function," said Lars Birgerson, M.D., Ph.D., Global Head Medical Affairs, Roche. "The ACTEMRA clinical development program was designed to establish ACTEMRA as a first-line biologic in the treatment of RA. When you consider that this is the fifth consecutive successful
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, has appointed ... and Managed Markets. Ms. Bauzon has a ... expanding payer coverage for laboratory services companies. She has ... with PerkinElmer, Inc., where she held the position of ...
(Date:8/21/2014)... 21, 2014  Publicis Groupe customer engagement agency ... Partner and Healthcare Industry Group Leader, has been featured ... the most inspiring people in the life-sciences industry. Those ... and development, marketing, technology, creativity, strategy and medicine. ... a partner in its leading Rosetta Consulting practice. In ...
(Date:8/21/2014)... CHARLOTTE, N.C. , Aug. 21, 2014 /PRNewswire-iReach/ ... Home Medical Equipment, Inc. for the third straight ... annual Inc. 500|5000, an exclusive ranking of the ... most comprehensive look at the most important segment ... Yelp, Pandora, Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Shannon Hartley Shines in PharmaVOICE 100 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... Kendle (Nasdaq: KNDL ), a leading, global ... of a planned succession Senior Vice President and COO Stephen ... Chairman and CEO Candace Kendle, PharmD, will continue to serve ... COO from Dr. Cutler will be Jamie Macdonald, who brings ...
... 14, 2011 Zoledronic acid (sold by Novartis as ... Tumor Metastasis, and Paget,s Disease with sales of $2 ... such as post-dose syndrome and osteonecrosis of the jaw. ... the administration of Zoledronic acid in combination with another ...
Cached Medicine Technology:Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 2Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 3Kendle Announces CEO Succession Plan, Promotes Stephen Cutler, PhD, to President and CEO 4ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination 2
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
(Date:8/21/2014)... 2014 The W. Montague Cobb/ ... a national voice in the elimination of health ... during the 112th National Medical Association’s (NMA) Annual ... , John Ruffin, Ph.D, former Director of the ... whose life-long career and innovations have had a ...
(Date:8/21/2014)... physicians in rural communities do not routinely screen ... Penn State medical and public health researchers. Rural ... limited resources if they seek help., "Rural health ... said Jennifer S. McCall-Hosenfeld, a primary care physician ... sciences, Penn State College of Medicine. "However, in ...
(Date:8/21/2014)... The report "Industrial Flue Gas ... System (FGD, DeNOx, Particulate Control, Mercury Control) by ... & Others) - Global Trends & Forecasts to ... gas treatment systems & services market with analysis ... terms of value. The industrial flue gas treatment ...
Breaking Medicine News(10 mins):Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2Health News:W. Montague Cobb/NMA Health Institute Honors Three Outstanding Leaders in Health Disparities 2Health News:Primary care physicians can be critical resource for abused women in rural areas 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... of Vermont will elevate the state to being the second ... health-care insurance// , which will cover nearly 96 percent of ... definitely relief for the 46 million Americans who are not ... and costs of insurance premium showing an upward trend, this ...
... getting dirtier despite promises, claimed patients in a survey despite ... ,The annual NHS patients survey has found high levels of ... questions were asked of the 80,000 people who took part ... ward ha been ‘very clean’ as compared to 56% in ...
... Scotland's health minister Andy Kerr said that the NHS staff ... latest statistics on NHS waiting times// as the "best ever". ... had reduced from 12 to 6 months. ,Reports ... number of outpatients and inpatient day cases with an 18-week ...
... cases of diarrhoea in Ranchi, the Jharkhand Health department ... with the disease. // ,'We have equipped ... free-of-cost treatment to patients,' Health and Family Welfare's joint ... patients to avail free treatment at the hospital instead ...
... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
... by the Indian Medical Association, the junior doctors of ... colleges today struck work launching a one-day strike. ... and government dental hospitals were 'totally shut down', emergency ... Assoication, BMC told PTI., ,'We will watch the ...
Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
For the quantitative determination of total cholesterol in serum....
For the quantitative in vitro determination of lithium in serum and plasma. Wavelength: 550 nm. Linear range: up to 4 mm....
... The ACS:180 SE is ... ACS:180 PLUS, consisting of important ... further simplify routine operation and ... represents the "Next Generation" ACS:180. ...
... of Platelet aggregometers allows to choose ... needs. Single, dual and four sample ... outputs or digital computer outputs. In ... which measure platelet aggregation in platelet-rich-plasma ...
Medicine Products: